High Neutrophil-Lymphocyte Ratio Linked to Worse Survival in Head and Neck Cancer
A high neutrophil-lymphocyte ratio appears to be an independent predictor of outcomes for some patients with head and neck cancer.
A high neutrophil-lymphocyte ratio appears to be an independent predictor of outcomes for some patients with head and neck cancer.
A comprehensive analysis of advanced kidney cancer tumors from the IMmotion151 trial provided new insights on the tumor features that underpin responses to therapy.
The ctDNA level at baseline was associated with response, PFS, and OS with pembrolizumab in patients with different tumor types.
Repeat biopsies may be needed prior to patient inclusion in targeted-therapy trials.
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.
A small study on patients with metastatic melanoma who were treated with autologous vaccines in a phase 2 clinical trial suggests that soluble PD-1 may have potential as a prognostic biomarker.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
An exploratory analysis showed that the VENTANA PD-L1 SP142 IHC assay had subpar concordance with 2 other PD-L1 IHC assays that are not approved for metastatic TNBC.
A sudden increase of serum-free light chains was associated with treatment-induced tumor lysis syndrome in multiple myeloma, suggesting a possible risk factor.